---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-002200"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2026-01-23T23:59:59+00:00"
generated_at: "2026-05-16T08:38:16.178434+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BioCryst closes $700M Astria acquisition, adds Phase 3 HAE asset navenibart

## Summary
- Acquired Astria for ~$700M net of cash; financed with $396.6M Blackstone loan and 37.3M shares.
- Adds navenibart (Phase 3 plasma kallikrein inhibitor) offering every-3/6-month HAE dosing.
- Astria CEO Jill Milne joins BioCryst board; John Ruesch becomes Chief Technical Operations Officer.
- BioCryst obtained $400M term loan from Blackstone funds (5-yr, SOFR+4.5% with PIK option).
- Astria's nine-month 2025 net loss $98.4M; had $227.7M cash/investments at Sep 30, 2025.

## SEC filing metadata
- accession: 0001140361-26-002200
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2026-01-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.01, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000114036126002200/0001140361-26-002200-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000114036126002200/ef20063492_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-002200
- JSON: https://secwatch.observer/filing/0001140361-26-002200.json
- Plain text: https://secwatch.observer/filing/0001140361-26-002200.txt

## Key facts
- Material Agreements
  BIOCRYST PHARMACEUTICALS INC entered into Loan Agreement with Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C., as Blackstone representatives, the lenders party thereto, and Wilmington Trust, National Association, as agent valued at $400 million (effective 2026-01-23).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C., as Blackstone representatives, the lenders party thereto, and Wilmington Trust, National Association, as agent
  - Value: $400 million
  - Effective: 2026-01-23
  source text: On January 23, 2026 (the “ Closing Date ”), BioCryst Pharmaceuticals, Inc., a Delaware corporation (“ BioCryst ”), entered into a Loan Agreement (the “ Loan Agreement ”), by and among BioCryst, as borrower, the guarantors from time to time party thereto, Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C., as the Blackstone representatives thereunder, the lenders from time to time party thereto and Wilmington Trust, National Association, as agent. The Loan Agreement provides for initial term loans in the principal amount of $400 million (the “ Term Loans ”), which were funded on the Closing Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/882796/000114036126002200/0001140361-26-002200-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.